[关于心力衰竭的历史]。

B Lüderitz
{"title":"[关于心力衰竭的历史]。","authors":"B Lüderitz","doi":"10.1007/s11789-011-0026-2","DOIUrl":null,"url":null,"abstract":"<p><p>The heart is by far the organ that is best known and has been identified for a long time. Myogenic weakness of the heart muscle pump with left-ventricular dysfunction remains the cardiac disease with the poorest prognosis while increasing in prevalence and incidence. Aside from all sorts of mystic treatment attempts and dubious herbal medicine, bloodletting was established early on as a superior remedy, which was applied in response to almost all cardiac illnesses. The first and perhaps most important cardiac drug was digitalis, the glycoside of the red and even more so of the white foxglove, described in 1552 by Leonhart Fuchs. In the 1980s, vasodilators and inotropic drugs supplemented the classical medications digitalis and diuretics. ACE inhibitors and beta-receptor blockers were added in the 1990s; at the turn of the millennium, the cardiac resynchronization therapy (CRT) and left-heart assist systems were developed; lately, there have been cellular and genetic approaches as well as xenotransplants. Preliminary results with stem cell technology are encouraging; however, it will be years until a clinical application-if it will happen at all.</p>","PeriodicalId":39208,"journal":{"name":"Clinical Research in Cardiology Supplements","volume":"6 ","pages":"2-5"},"PeriodicalIF":0.0000,"publicationDate":"2011-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11789-011-0026-2","citationCount":"2","resultStr":"{\"title\":\"[On the history of heart failure].\",\"authors\":\"B Lüderitz\",\"doi\":\"10.1007/s11789-011-0026-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The heart is by far the organ that is best known and has been identified for a long time. Myogenic weakness of the heart muscle pump with left-ventricular dysfunction remains the cardiac disease with the poorest prognosis while increasing in prevalence and incidence. Aside from all sorts of mystic treatment attempts and dubious herbal medicine, bloodletting was established early on as a superior remedy, which was applied in response to almost all cardiac illnesses. The first and perhaps most important cardiac drug was digitalis, the glycoside of the red and even more so of the white foxglove, described in 1552 by Leonhart Fuchs. In the 1980s, vasodilators and inotropic drugs supplemented the classical medications digitalis and diuretics. ACE inhibitors and beta-receptor blockers were added in the 1990s; at the turn of the millennium, the cardiac resynchronization therapy (CRT) and left-heart assist systems were developed; lately, there have been cellular and genetic approaches as well as xenotransplants. Preliminary results with stem cell technology are encouraging; however, it will be years until a clinical application-if it will happen at all.</p>\",\"PeriodicalId\":39208,\"journal\":{\"name\":\"Clinical Research in Cardiology Supplements\",\"volume\":\"6 \",\"pages\":\"2-5\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s11789-011-0026-2\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Research in Cardiology Supplements\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s11789-011-0026-2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Research in Cardiology Supplements","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11789-011-0026-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2

摘要

到目前为止,心脏是最著名的器官,而且已经被发现很长时间了。心肌泵肌源性无力合并左心室功能不全是预后最差的心脏病,但其患病率和发病率均在增加。除了各种神秘的治疗尝试和可疑的草药,放血很早就被确立为一种优越的治疗方法,几乎适用于所有心脏疾病。第一个,也许也是最重要的心脏药物是洋地黄,它是红色毛地黄的糖苷,更重要的是白色毛地黄,Leonhart Fuchs在1552年描述了它。在20世纪80年代,血管扩张剂和肌力药物补充了传统的药物洋地黄和利尿剂。ACE抑制剂和β受体阻滞剂在20世纪90年代加入;在世纪之交,心脏再同步化治疗(CRT)和左心辅助系统被开发出来;最近,有细胞和遗传方法以及异种移植。干细胞技术的初步结果令人鼓舞;然而,临床应用还需要数年时间——如果真能实现的话。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[On the history of heart failure].

The heart is by far the organ that is best known and has been identified for a long time. Myogenic weakness of the heart muscle pump with left-ventricular dysfunction remains the cardiac disease with the poorest prognosis while increasing in prevalence and incidence. Aside from all sorts of mystic treatment attempts and dubious herbal medicine, bloodletting was established early on as a superior remedy, which was applied in response to almost all cardiac illnesses. The first and perhaps most important cardiac drug was digitalis, the glycoside of the red and even more so of the white foxglove, described in 1552 by Leonhart Fuchs. In the 1980s, vasodilators and inotropic drugs supplemented the classical medications digitalis and diuretics. ACE inhibitors and beta-receptor blockers were added in the 1990s; at the turn of the millennium, the cardiac resynchronization therapy (CRT) and left-heart assist systems were developed; lately, there have been cellular and genetic approaches as well as xenotransplants. Preliminary results with stem cell technology are encouraging; however, it will be years until a clinical application-if it will happen at all.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical Research in Cardiology Supplements
Clinical Research in Cardiology Supplements Medicine-Radiology, Nuclear Medicine and Imaging
CiteScore
6.10
自引率
0.00%
发文量
0
期刊最新文献
Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels. Is lipoprotein(a) a risk factor for ischemic stroke and venous thromboembolism? Lipoprotein(a) and mortality-a high risk relationship. Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors. Lipoprotein(a)-an interdisciplinary challenge.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1